WILSON THERAPEUTICS AB (PUBL)

INTERIM REPORT JANUARY 1 – JUNE 30, 2016

April 1 – June 30, 2016
- Net sales amounted to SEK 0.0 M (0.0)
- Loss for the period was SEK 26.9 M (loss: 16.7)
- Loss per share, before and after dilution, totaled SEK 1.66 (loss: 13.14)
- At June 30, cash and cash equivalents amounted to SEK 435.6 M (26.8)

January 1 – June 30, 2016
- Net sales amounted to SEK 0.0 M (0.0)
- Loss for the period was SEK 49.2 M (loss: 30.5)
- Loss per share, before and after dilution, totaled SEK 5.86 (loss: 24.07)

Significant events during the period January 1 – June 30, 2016
- A new share issue raised SEK 39.9 M after issue costs
- Resolution regarding a 1:10 share split
- Data from the ongoing Phase II trial of Decuprate® presented at major European conferences
- Wilson Therapeutics was listed in the Mid Cap segment on Nasdaq Stockholm, raising SEK 402.7 M after issue costs
- Ongoing phase II study fully enrolled
- Rick Lilley appointed as Chief Regulatory Officer

Significant events after the end of the reporting period
- Vincent Metzler appointed as Vice President Commercial Planning & Launch Strategy

"Data from our ongoing phase II trial continue to indicate that Decuprate® has the potential to address the unmet medical needs in Wilson Disease. Although the results are promising it is important to underline that these results are preliminary as the study is still ongoing but it will be very exciting to follow the trial completion during the end of the year."

Jonas Hansson, CEO, Wilson Therapeutics.

Financial overview of the Group

Amounts in SEK 000s	Apr–Jun		Jan–Jun		Jan–Dec
	2016	2015	2016	2015	2015
Net sales	-	-	-	-	-
Operating loss	-26,871	-16,699	-49,157	-30,351	-70,283
Loss for the period	-26,891	-16,710	-49,171	-30,504	-70,507
Loss per share, before/after dilution (SEK)[1)]	-1.66	-13.14	-5.86	-24.07	-55.53
Equity at the end of the period	484,383	80,550	484,383	80,550	84,562
Cash flow from operating activities	-20,143	-11,992	-38,447	-26,134	-61,495
Cash and cash equivalents at the end of the period	435,621	26,777	435,621	26,777	31,404

1) Adjusted for share split 1:10 resolved in April 2016.

CEO STATEMENT

Encouraging preliminary data from ongoing clinical trial
Our operational focus in 2016 is to advance the ongoing phase II trial in Wilson Disease patients with our product candidate Decuprate®. The study is conducted at 11 centers in the US and EU, with the aim to learn more about the dosing of Decuprate® as well as the proposed clinical endpoints for the upcoming pivotal phase III program.

The ongoing trial is an open label, non-comparator study, which means that all subjects in the study receive Decuprate® as monotherapy. Patient enrollment progressed well during the spring, and in May, the 28th and last patient was included in the trial. During the spring, we also presented preliminary data from the study at three major scientific meetings.

The latest data summary was compiled on August 3 when half of the 28 included patients had completed the 24 weeks principal part of the study. These data continue to indicate that Decuprate® is efficacious, has a high response rate, and that it is generally well tolerated. Combined with the expected once daily dosing, we hope this could lead to significant improvements for patients living with Wilson Disease. Although the results are promising, it is important to underline that these results are preliminary as the study is still ongoing.

We are now looking forward to receive the full dataset from the study late 2016 or early 2017. After we have received and analyzed the data for all patients, the plan is to go back to the regulatory agencies and discuss the final design of the pivotal program. If everything proceeds as planned, we intend to start the phase III trial in 2017.

Expanded organization
During the summer we have also made two key recruitments to further strengthen the management team.

In June we recruited Rick Lilley as Chief Regulatory Officer. Dr. Lilley is a senior regulatory executive with more than 30 years of experience in the pharmaceutical and biotech industries. Most recently he served as Head of Global Regulatory Affairs at Vertex Pharmaceuticals. Prior to Vertex, he held senior positions at UCB, Johnson & Johnson, Shire and AstraZeneca. Rick has successfully led the regulatory process to approval for more than 20 products.

In August we recruited Vincent Metzler as Vice President Commercial Planning & Launch Strategy. Dr. Metzler is a senior marketing & commercial operations executive with an extensive rare disease background and more than 16 years of experience in the pharmaceutical and biotech industries. Vincent joins Wilson from Alexion where he served as Senior Director Marketing in Europe, playing an instrumental role in launching and building the commercial success of Soliris in the EMEA region and was a core member of the Global Soliris Leadership Team. Prior to Alexion Vincent held various sales and marketing positions at Miltenyi Biotec, Roche and Amgen.

I am fully convinced that their respective knowledge and experience will be tremendously valuable for us as we move the Decuprate® program forward and prepare for a future potential launch.

Wilson Therapeutics completed IPO
On May 12, Wilson Therapeutics completed its Initial Public Offering (IPO) and was listed in the Mid Cap segment on Nasdaq Stockholm. The IPO received strong interest both in Sweden and internationally and the offering was well oversubscribed. The existing main shareholders all subscribed for new shares in the offering alongside several other well-renowned institutional long term investors. There was also a significant interest from retail investors; in all approximately 3,000 new shareholders participated in the offering. I would like to use this opportunity to thank both our new and existing shareholders again for the confidence shown in us.

Full financing to take Decuprate® through clinical development
Operating costs during the first six months of the year amounted to SEK 49.2 M (30.4). The increase was due mainly to costs for the IPO, higher clinical costs related to the ongoing trial and higher costs for our stock option program. In March, a new share issue raised SEK 40 M after issue expenses from the company's existing shareholders. We raised an additional SEK 403 M after issue expenses in the IPO. This means that we have secured long term financing that is expected to be sufficient to take Decuprate® all the way through clinical development in the US and EU, provided the feedback from regulatory authorities continues to support the current development plan.

Exciting years ahead
Following the IPO, we are well equipped for the remainder of 2016. We will present additional preliminary data at The Liver Meeting® in Boston, November 11-15, followed by the final topline results from the phase II study late 2016 or early 2017. With the financing secured we can also continue to prepare the phase III program at full speed.

There have not been any new drugs developed for Wilson Disease in several decades, and significant unmet medical needs still exist. The physicians, as well as the patients and their families, are therefore very supportive of our work on Decuprate®, as the drug has shown potential to address these unmet needs. If we are successful all the way to market, we may significantly improve the quality of life for the patients. This is evidently a great source of inspiration for all of us in the company, and we have high hopes that 2016 will end as successfully as it has started.

Stockholm August 18, 2016

Jonas Hansson
CEO, Wilson Therapeutics AB (publ)

PROJECT OVERVIEW

Pipeline

Product	Indication	Preclinical	Phase I	Phase II	Phase III	Reg.
Decuprate®	Wilson Disease					
	Familial ALS					

Wilson Disease

Wilson Disease is a rare genetic disease that causes serious copper poisoning. The genetic defect causes excessive copper accumulation, primarily in the liver and/or the central nervous system, and the disease results in life-threatening damage to the liver and brain if left untreated. Wilson Disease affects approximately one in every 30,000 people worldwide, corresponding to a prevalence of approximately 10,000 patients in the US and 15,000 patients in the EU.

The treatment goal in Wilson Disease is to reduce and maintain free copper at normal levels and as a result to improve the patients' symptoms. The drugs available today for the treatment of Wilson Disease are penicillamine and trientine, which are so called copper chelators, binding and reducing the body's copper levels by increasing urinary copper excretion, and zinc. Zinc reduces the dietary uptake copper in the gut.

These treatments were introduced in the 50's and 60's and are all associated with significant shortcomings. The process of reducing copper with the copper chelators is relatively slow and the improvement of clinical symptoms can take years. They are non-specific to copper and also bind to other metals like iron, zinc and calcium. The copper chelators also have severe side effects. One of the most serious side effects is that, in approximately 25 percent of the cases, patients suffering from neurological symptoms experience a drug-induced worsening of neurological symptoms shortly after initiation of therapy. Of the patients experiencing this worsening, up to 50 percent never recover.

The chelators should be taken up to four times daily on an empty stomach which often leads to poor treatment compliance. Zinc is not recommended as an initial therapy of symptomatic patients with Wilson Disease because of the slow onset of action. Zinc therapy has shown to be less efficacious than chelation therapy, and gastrointestinal symptoms such as discomfort or pain are relatively common side effects. Like the chelators, zinc should also be taken multiple (up to five) times per day on an empty stomach.

Decuprate® is a first in class agent for the reduction of copper, under investigation as a novel therapy in Wilson Disease. Decuprate®, unlike current treatments for Wilson Disease, appears to have direct activity in the liver, where it specifically targets and reduces toxic free copper. Decuprate® also reduces toxic free copper in the blood, which is believed to be excreted via the bile, the body's natural route for excess copper elimination. The active ingredient of Decuprate®,

tetrathiomolybdate, has been tested in several clinical studies in Wilson Disease patients. Data from these studies, as well as preliminary data from the company's ongoing phase II study, suggest that Decuprate® can rapidly lower and control toxic free copper levels and improve clinical symptoms in these patients.

The data also suggest that Decuprate® is generally well-tolerated with the potential for a reduced risk of neurological worsening after initiation of therapy compared to existing therapies. Decuprate® is expected to have a once-daily dosing regimen, which may potentially translate into improved compliance in Wilson Disease patients, leading to fewer treatment failures and ultimately improved outcomes as a result. Decuprate® has received orphan drug designation for the treatment of Wilson Disease in the US and EU.

Project status

Since November 2014, an open-label Phase II trial is ongoing, evaluating the efficacy and safety of Decuprate® monotherapy dosed once-daily in 28 newly-diagnosed patients with Wilson Disease, aged 18 years and older, who are previously untreated or have received a standard of care agent for up to two years. The study is being conducted at eleven sites in the US and Europe and will follow patients on Decuprate® for 24 weeks. Patients completing the 24 weeks can elect to maintain treatment with Decuprate® in an extension phase of the study.

The last patient was enrolled in the trial on May 18 and as of August 3, 14 patients have reached the end of the 24 week treatment period. All 14 patients have elected to go into the extension phase. The patients recruited had various degrees of hepatic impairment at the time of enrollment, and the majority of enrolled patients also had neurological symptoms at study start.

The preliminary data as of August 3 show that the patients' liver status, measured using the Revised King's Score (Modified Nazer Score), had stabilized or improved in 24 out of 27 evaluable patients at the last observation compared to baseline. Neurological impairment was measured by a neurology scale specific for Wilson Disease (UWDRS 3). The neurological status has improved or remained stable in 24 out of the 27 evaluable patients when comparing the last UWDRS 3 assessment with baseline.

Both the average King's score and the average UWDRS 3 score continued to indicate clinical improvement during the treatment period for the patients that have completed the 24 weeks. Treatment with Decuprate® was generally well-tolerated. To date, no drug-induced neurological worsening has been observed upon treatment initiation. This is in line with the low incidence of drug-induced neurological worsening described in the previously published data on ammonium tetrathiomolybdate. Levels of free copper were reduced over the duration of treatment.

Additional preliminary data are planned to be presented at The Liver Meeting® in Boston November 11-15. Topline results from the trial are expected late 2016 or early 2017.

ALS

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease, in which the nerve cells controlling the body's muscles gradually atrophy, leading to general paralysis and respiratory failure. There is one approved drug on the market that prolongs survival by a few months, but there is no effective treatment to control the disease. Median survival for an ALS patient is three to five years. About 1.5 to 2.5 per 100,000 people are diagnosed with ALS every year, and about 30,000 people suffer from the disease in the EU and the US. About 10 percent of patients have a family history of ALS (familial ALS). Of the patients with familial ALS, about 20 percent have a mutation in the gene coding for an enzyme known as superoxide dismutase 1 (SOD1).

Project status

Wilson Therapeutics is exploring the possibility of developing Decuprate® for the treatment of patients with SOD1-familial ALS.

SIGNIFICANT EVENTS

Events during the period January 1 – June 30, 2016

New share issue executed
In March 2016, a new share issue raised SEK 40.0 M from the company's principal shareholders, before issue expenses of SEK 0.1 M. The issue comprised 1,510,840 Class B preference shares, adjusted for a 1:10 share split resolved in April 2016. The issue was conditional on the recruitment of patients for the company's ongoing clinical Phase II trial of Decuprate® progressing according to plan, and the issue was executed when the recruitment target was achieved.

Share-split resolved
The Annual General Meeting on April 4, 2016 resolved to implement a 1:10 share split. After the share split, the total number of shares was 16,830,100, comprising 1,450,000 ordinary shares, 3,018,200 Class A preference shares and 12,361,900 Class B preference shares. The share split also impacted the company's employee stock option program and increased the number of options outstanding 1:10.

Data from the ongoing Phase II trial of Decuprate® were presented at major European conferences
In April 2016, data from the company's ongoing Phase II trial of Decuprate® were presented at the International Liver Congress™ 2016 in Barcelona. The presentation was made by Prof. Karl Heinz Weiss from the University of Heidelberg. Additional data from the study were presented at The 2nd Congress of the European Academy of Neurology in Copenhagen in May, and at The 20th International Congress of Parkinson´s Disease and Movement Disorders in Berlin in June. These presentations were made by Prof. Anna Czlonkowska from the Medical University of Warsaw.

Wilson Therapeutics was listed on Nasdaq Stockholm in the Mid Cap segment
On May 12, Wilson Therapeutics completed its IPO and was listed on Nasdaq Stockholm in the Mid Cap segment. In connection with the listing, all existing preference shares were converted into common shares and 8,890,148 new common shares were issued. The introduction price was set at SEK 49 per share and the IPO raised SEK 435.6 M before issue expenses of SEK 32.9 M. The number of shares outstanding after the IPO amounts to 25,720,248.

Ongoing phase II study fully enrolled
On May 18, treatment of the 28th and last patient was dosed in the company's ongoing phase II trial evaluating Decuprate® as a treatment for Wilson Disease.

Rick Lilley appointed as Chief Regulatory Officer
In June Rick Lilley was appointed as Chief Regulatory Officer. Dr. Lilley reports to CEO Jonas Hansson and is a member the company's management team.

Events after the end of the report period

Vincent Metzler appointed as Vice President Commercial Planning & Launch Strategy
In August Vincent Metzler was appointed as Vice President Commercial Planning & Launch Strategy. Dr. Metzler reports to CEO Jonas Hansson and is a member the company's management team.

FINANCIAL INFORMATION

Sales and earnings for the second quarter of 2016
Sales amounted to SEK 0.0 M (0.0) and the operating result deteriorated to a loss of SEK 26.9 M (loss: 16.7). The loss for the second quarter was SEK 26.9 M (loss: 16.7). The cost increase was due mainly to higher costs connected to the ongoing phase II clinical trial, costs related to the IPO and costs for the company's stock option program.

Sales and earnings for the first six months of 2016

Revenue
Sales amounted to SEK 0.0 M (0.0) during the period. The company is not expected to generate any revenue until its products are launched onto the market.

Sales and administrative expenses
During the period, sales and administrative expenses rose to SEK 20.8 M (7.7). The increase was mainly due to the cost of the IPO amounting to SEK 6.8 M (0.0). Costs also increased for the company's employee stock option program and for the build-up of an accounting function.

Research and development expenditure
During the quarter, research and development expenditure increased to SEK 28.2 M (22.7). The increase was mainly due to increased costs for the ongoing Phase II clinical trial and for preclinical experiments, and to increased costs for the company's employee stock option program.

Earnings
Loss for the first quarter totaled SEK 49.2 M (loss: 30.5), resulting in a loss per share, before and after dilution, of SEK 5.86 (loss: 24.07).

Liquidity and financing
In the first six months of the year, cash flow from operating activities declined to a negative SEK 38.4 M (neg: 26.1), largely due to increased costs for clinical trials and for the IPO. Cash flow from investing activities was SEK 0.0 M (0.0).

Cash flow from financing activities amounted to SEK 442.6. M (29.9), attributable to new share issues. The first new share issue, that was executed in March 2016, comprised 1,510,840 Class B preference shares adjusted for a 1:10 share split resolved in April 2016, and raised SEK 40.0 M before issue costs of SEK 0.1 M. In connection with the IPO in May 8,890,148 new common shares were issued, which raised SEK 435.6 M before issue costs of SEK 32.9 M. In total the new share issues raised SEK 475.6 M (30.0) before issue costs of SEK 33.0 M (0.1).

Cash flow for the period was SEK 404.2 M (3.8). At June 30, 2016, cash and cash equivalents amounted to SEK 435.6 M, compared with SEK 26.8 M at June 30, 2015.

Share-based incentive program
The purpose of share-based incentive programs is to promote the company's long-term interests by motivating and rewarding the company's senior executives and other employees. Wilson Therapeutics currently has one employee stock option program comprising all employees, certain Board members and certain consultants. Program costs of SEK 9.6 M (1.7) were charged

to earnings for the period but have no cash impact. During the period 110 000 stock options have been granted and no stock options have been exercised. At June 30, 2016, the number of granted stock options amounted to 1,765,000 (528,000), where the number of stock options outstanding 2015 has been adjusted for share split 1:10 decided in April 2016. The company's other provisions amounting to SEK 6.7 M (2.0) are provisions for social contributions related to the stock option program.

Investments
Fixed assets mainly consist of intellectual property rights. During the quarter, investments in intangible fixed assets amounted to SEK 0.0 M (0.0) and investments in tangible fixed assets to SEK 0.0 M (0.0).

Employees
At June 30, 2016, Wilson Therapeutics had 9 (6) employees. The average number of employees during the first six months of the year was 8 (6).

Parent Company
Since the operations of the Parent Company are consistent with those of the Group in all material respects, the comments for the Group are also largely relevant for the Parent Company.

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

Amounts in SEK 000s	Apr–Jun		Jan–Jun		Jan–Dec
	2016	2015	2016	2015	2015
Net sales	-	-	-	-	-
Gross profit	**-**	**-**	**-**	**-**	**-**
Sales and administrative expenses	-11,726	-4,702	-20,835	-7,674	-17,357
Research and development expenses	-15,046	-11,997	-28,201	-22,677	-52,961
Other operating revenue	-	-	20	-	35
Other operating expenses	-99	0	-141	0	-
Operating loss	**-26,871**	**-16,699**	**-49,157**	**-30,351**	**-70,283**
Net financial items	0	-11	1	-55	-57
Loss before tax	**-26,871**	**-16,710**	**-49,156**	**-30,406**	**-70,340**
Tax	-20	0	-15	-98	-167
Loss for the period[1)]	**-26,891**	**-16,710**	**-49,171**	**-30,504**	**-70,507**
Other comprehensive income					
Items that will be reclassified to profit or loss					
Translation difference for the period	43	11	18	34	44
Other comprehensive income after tax for the period	**43**	**11**	**18**	**34**	**44**
Comprehensive loss for the period[1)]	**-26,848**	**-16,699**	**-49,153**	**-30,470**	**-70,463**
Loss per share, before/after dilution (SEK)[2)]	-1.66	-13.14	-5.86	-24.07	-55.53

1) 100% attributable to Parent Company shareholders.
2) Adjusted for share split 1:10 resolved in April 2016. Earnings per share calculated as earnings per common share, where the result is adjusted for the right of preference shareholders to receive a dividend for the period. During the period all preference shares have been converted into common shares in connection with the stock market listing.

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

Amounts in SEK 000s	JUN 30, 2016	JUN 30, 2015	DEC 31, 2015
ASSETS			
Intangible fixed assets	64,632	64,632	64,632
Tangible fixed assets	6	20	13
Financial fixed assets	54	54	54
Total fixed assets	**64,692**	**64,706**	**64,699**
Current receivables	2,704	415	2,164
Cash and cash equivalents	435,621	26,777	31,404
Total current assets	**438,325**	**27,192**	**33,568**
TOTAL ASSETS	**503,017**	**91,898**	**98,267**
EQUITY AND LIABILITIES			
Equity attributable to shareholders of the parent company	484,383	80,550	84,562
Deferred tax liabilities	-	3	-
Other provisions	6,774	1,966	3,447
Total non-current liabilities	**6,774**	**1,969**	**3,447**
Accounts payable	5,964	3,994	3,119
Other current liabilities	5,896	5,385	7,139
Total current liabilities	**11 860**	**9 379**	**10 258**
TOTAL EQUITY AND LIABILITIES	**503,017**	**91,898**	**98,267**

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Amounts in SEK 000s	Apr–Jun		Jan–Jun		Jan–Dec
	2016	2015	2016	2015	2015
Opening balance	**105,024**	**66,921**	**84,562**	**80,125**	**80,125**
Comprehensive loss for the period	**-26,848**	**-16,699**	**-49,153**	**-30,470**	**-70,463**
Transactions with owners					
New share issue	435,617	30,000	475,617	30,000	70,000
Costs attributable to new share issue	-32,876	-87	-32,976	-87	-107
Employee stock option program	3,466	415	6,333	982	5,007
Total transactions with owners	**406,207**	**30,328**	**448,974**	**30,895**	**74,900**
Closing balance	**484,383**	**80,550**	**484,383**	**80,550**	**84,562**

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW

Amounts in SEK 000s	Apr–Jun		Jan–Jun		Jan–Dec
	2016	2015	2016	2015	2015
Operating loss	-26,871	-16,699	-49,157	-30,351	-70,283
Adjustment for non-cash items[1)]	5,932	975	9,667	1,738	7,262
Interest received	1	3	1	3	0
Interest paid	-6	-2	-6	-3	-5
Tax paid	77	-47	-71	-175	-267
Cash flow from operating activities before changes in working capital	**-20,867**	**-15,770**	**-39,566**	**-28,788**	**-63,293**
Cash flow from changes in working capital	724	3,778	1,119	2,654	1,798
Cash flow from operating activities	**-20,143**	**-11,992**	**-38,447**	**-26,134**	**-61,495**
Cash flow from investing activities	-	-	-	-	-
Cash flow from financing activities	402,742	29,913	442,641	29,913	69,893
Cash flow for the period	**382,599**	**17,921**	**404,194**	**3,779**	**8,398**
Cash and cash equivalents at the beginning of the period	52,988	8,878	31,404	23,011	23,011
Exchange-rate difference in cash and cash equivalents	34	-22	23	-13	-5
Cash and cash equivalents at the end of the period	**435,621**	**26,777**	**435,621**	**26,777**	**31,404**

1) Pertains mainly to costs of employee stock option program including social contributions.

CONDENSED PARENT COMPANY PROFIT AND LOSS STATEMENT

Amounts in SEK 000s	Apr–Jun		Jan–Jun		Jan–Dec
	2016	2015	2016	2015	2015
Net sales	-	-	-	-	-
Gross profit	**-**	**-**	**-**	**-**	**-**
Sales and administrative expenses	-11,719	-4,648	-20,766	-7,570	-17,180
Research and development expenditure	-15,067	-12,408	-28,259	-22,438	-53,576
Other operating revenue	-	-	-	-	35
Other operating expenses	-99	-	-141	-	-
Operating loss	**-26,885**	**-17,056**	**-49,166**	**-30,008**	**-70,721**
Profit/loss from financial items	1	-11	1	-55	-82
Loss after financial items	**-26,884**	**-17,067**	**-49,165**	**-30,063**	**-70,803**
Tax	-	-	-	-	-
Loss for the period	**-26,884**	**-17,067**	**-49,165**	**-30,063**	**-70,803**

CONDENSED PARENT COMPANY STATEMENT OF COMPREHENSIVE INCOME

Amounts in SEK 000s	Apr–Jun		Jan–Jun		Jan–Dec
	2016	2015	2016	2015	2015
Loss for the period	-26,884	-17,067	-49,165	-30,063	-70,803
Other comprehensive income	-	-	-	-	-
Comprehensive loss for the period	**-26,884**	**-17,067**	**-49,165**	**-30,063**	**-70,803**

CONDENSED PARENT COMPANY BALANCE SHEET

Amounts in SEK 000s	JUN 30, 2016	JUN 30, 2015	DEC 31, 2015
ASSETS			
Intangible fixed assets	32,360	32,360	32,360
Tangible fixed assets	6	20	13
Financial fixed assets	32,485	32,485	32,485
Total fixed assets	**64,851**	**64,865**	**64,858**
Current receivables	2,721	416	2,237
Cash and cash equivalents	434,458	26,246	31,063
Total current assets	**434,179**	**26,662**	**33,300**
TOTAL ASSETS	**502,030**	**91,527**	**98,158**
EQUITY AND LIABILITIES			
Equity			
Restricted shareholders' equity	2,858	1,258	1,702
Unrestricted shareholders' equity	480,602	79,128	81,949
Total Equity	**483,460**	**80,386**	**83,651**
Other provisions	**6,774**	**1,965**	**3,447**
Current liabilities			
Accounts payable	5,847	3,986	3,096
Other current liabilities	5,949	5,190	7,964
Total current liabilities	**11,796**	**9,176**	**11,060**
TOTAL EQUITY AND LIABILITIES	**502,030**	**91,527**	**98,158**

CHANGE IN NUMBER OF SHARES

	Apr–Jun		Jan–Jun		Jan–Dec
	2016	2015	2016	2015	2015
Total number of shares, opening balance	1,683,010	731,928	1,531,926	731,928	731,928
Shares added through share split 1:10	15,147,090	-	15,147,090	-	-
Shares added through new share issues	8,890,148	399,998	9,041,232	399,998	799,998
Total number of shares, closing balance	**25,720,248**	**1,131,926**	**25,720,248**	**1,131,926**	**1,531,926**

OTHER INFORMATION

Accounting policies in accordance with IFRS
This interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and the applicable provisions of the Swedish Annual Accounts Act. The interim report for the Parent Company has been prepared pursuant to Chapter 9 of the Swedish Annual Accounts Act, Interim Financial Reporting. The same accounting policies and measurement criteria have been applied for the Group and the Parent Company as in the 2015 Annual Report. New or revised IFRS requirements introduced in 2016 have not affected Wilson Therapeutics during the period.

New ESMA guidelines for key ratios have taken effect during the period. The group does not present any alternative key ratios as no such key ratios are deemed necessary to understand the group activities.

Risks and uncertainties in the Group and Parent Company

Operational risks
Research and drug development up to approved registration is subject to considerable risk and is a capital-intensive process. The majority of all initiated projects will never reach market registration due to the technological risk such as the risk for insufficient efficacy, intolerable side effects or manufacturing problems. If competing pharmaceuticals capture market share or reach the market faster, or if competing research projects achieve better product profile, the future value of the product portfolio may be lower than expected. The operations may also be impacted negatively by regulatory decisions, such as approvals and price changes.

Financial risk management
Wilson Therapeutics' financial policy governing the management of financial risks has been designed by the Board of Directors and represents a framework of guidelines and rules in the form of risk mandates and limits for financial activities. Wilson Therapeutics is primarily affected by foreign-exchange risk. A considerable portion of the company's costs is denominated in USD and EUR. In accordance with the established financial policy, no currency hedging has been employed. The financial policy is updated at least once annually.

For a more detailed description of risks and uncertainties, refer to Note 18 in the 2015 Annual Report.

Financial instruments
Wilson Therapeutics' financial assets and liabilities comprise cash and cash equivalents, accrued expenses and accounts payable. Therefore, the fair values of all financial instruments are approximately equal to their carrying amounts, since all maturities are short. Wilson Therapeutics has not applied net accounting to any financial assets or liabilities, and has no agreements that permit offsetting.

The company's cash and cash equivalents consists of cash deposits at the company's bank.

Related-party transactions
During the period a new share issue directed at the major shareholders was executed. No other transactions have taken place between the company and its related parties that could materially affect the company's position and earnings for the period.

Estimates and judgments
Preparation of the interim report requires management to make estimates that affect the reported amounts of assets, liabilities, revenues and expenses. Actual outcomes may deviate from these estimates. The key sources of estimation uncertainty are the same as those outlined in Note 2 of the 2015 Annual Report.

Review
This interim report has not been reviewed by the company's auditors.

The Board of Directors and CEO declare that the undersigned interim report provides a fair overview of the parent company's and Group's operations, their financial position and performance, and describes material risks and uncertainties facing the parent company and other companies in the Group.

Stockholm August 18, 2016

Andrew Kay
Chairman of the Board

Dina Chaya
Member of the Board

Genghis Lloyd-Harris
Member of the Board

Bali Muralidhar
Member of the Board

Hans Schikan
Member of the Board

Mårten Steen
Member of the Board

Jonas Hansson
CEO

The information in the interim report is such that Wilson Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication on August 18, 2016 at 8:00 a.m. CET.

For further information contact:
Jonas Hansson, CEO, Wilson Therapeutics AB
Telephone: +46 8 796 00 00
Email: jonas.hansson@wilsontx.eu

Wilson Therapeutics AB (publ)
Corp. Reg. No. 556893-0357
Västra Trädgårdsgatan 15
SE-111 53 Stockholm, Sweden

Financial calendar

Interim report for the third quarter	November 25, 2016
Year-end report	February 23, 2017

About Wilson Therapeutics

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics' lead product, Decuprate®, is initially being developed as a novel treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.

More information is available at www.wilsontherapeutics.com.